Drug intelligence / Profile preview

LMWC-BRNPs

Development stage: Preclinical
Modality: Nanoparticles → Drug Delivery Systems
Administration: Oral

Overview

LMWC-BRNPs is an oral nanomedicine comprising bilirubin-conjugated low molecular weight water-soluble chitosan. It is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In mouse models, LMWC-BRNPs are readily absorbed upon oral administration and reach the liver, where they are primarily taken up by liver macrophages and hepatic stellate cells. The drug modulates dysregulated hepatic immunity to alleviate inflammation and prevents uncontrolled fat deposition by activating peroxisome proliferator-activated receptor-alpha (PPAR-α) and its target genes, thereby reducing fibrosis and oxidative stress.

Other names: bilirubin-conjugated low molecular weight water-soluble chitosan

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on LMWC-BRNPs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LMWC-BRNPs.

Explore the full profile